Published in Drug Alcohol Depend on October 09, 2015
Opioid withdrawal suppression efficacy of oral dronabinol in opioid dependent humans. Drug Alcohol Depend (2016) 0.75
Opioid antagonism of cannabinoid effects: differences between marijuana smokers and nonmarijuana smokers. Neuropsychopharmacology (2006) 1.37
Compartment-specific localization of cannabinoid 1 (CB1) and mu-opioid receptors in rat nucleus accumbens. Neuroscience (2004) 1.36
Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice. J Pharmacol Exp Ther (2001) 1.27
Interaction of the cannabinoid and opioid systems in the modulation of nociception. Int Rev Psychiatry (2009) 1.16
Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal. Neuroscience (2013) 1.14
Modulation of oral morphine antinociceptive tolerance and naloxone-precipitated withdrawal signs by oral Delta 9-tetrahydrocannabinol. J Pharmacol Exp Ther (2003) 1.12
Characterization of cannabinoid-1 receptors in the locus coeruleus: relationship with mu-opioid receptors. Brain Res (2009) 1.07
CB1 cannabinoid receptor antagonist-induced opiate withdrawal in morphine-dependent rats. Neuroreport (1998) 1.03
Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions. Br J Pharmacol (2007) 1.01
Cardiovascular effects of intravenous delta-9-tetrahydrocannabinol: autonomic nervous mechanisms. Clin Pharmacol Ther (1979) 1.00
Subjective, cognitive and cardiovascular dose-effect profile of nabilone and dronabinol in marijuana smokers. Addict Biol (2012) 0.99
Pharmacokinetics of cannabinoids. Pain Res Manag (2005) 0.96
The effects of delta-9-tetrahydrocannabinol (cannabis) on cardiac performance with and without beta blockade. Circulation (1976) 0.95
A new face of endocannabinoids in pharmacotherapy. Part I: protective role of endocannabinoids in hypertension and myocardial infarction. J Physiol Pharmacol (2014) 0.87
The effects of dronabinol during detoxification and the initiation of treatment with extended release naltrexone. Drug Alcohol Depend (2015) 0.87